Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
accretive, Acumen, Aducanumab, allied, Alzheimer, amyloid, antagonist, antidote, antiviral, Aptevo, Aricept, Austria, Bapineuzumab, Battelle, beta, biospecific, blockade, Brain, broader, Burkholderia, buying, Camden, CEO, Chimp, Chinese, CHO, cholinesterase, CIHR, civilian, Cognex, consummated, consummation, covenant, Crenezumab, Crohn, cSNK, culminate, cytokine, deferral, dengue, discernible, EBOZ, EID, Eisai, Eli, Emergard, engineered, enterprise, Entyvio, epitope, ERP, evolved, Exelon, explicitly, figured, GMP, hamster, harmonized, HUMIRA, iminosugar, imminent, immunopathological, immunosuppressive, implicitly, Imputation, Index, inhibiting, inhibition, insoluble, ITAR, leader, Lilly, Lonza, mAb, meaningfully, Memorial, monomer, MVA, Namenda, NanoBio, Nemera, neurodegeneration, neurotoxic, NMDA, noncurrent, oligomer, oligomeric, oltertuzumab, ovary, partnership, perioperative, Pharma, PII, PIII, plaque, play, Ponezumab, proven, Razadyne, recast, Remicade, reprotoxicity, retrospective, retrospectively, seasoned, Senegal, Solanezumab, soluble, split, Stelara, subcutaneously, Subtopic, suppression, Takeda, thirteen, today, Traffic, unchanged, Unither, unlock, unrestricted, unvested, UV, UVX, Virology, Xeljanz
Removed:
BCA, budget, cancellation, collectibility, committing, conclusion, controlling, created, CVR, dating, deficit, developmental, diversifying, dosed, encourage, enforcing, EPDU, EUA, exclude, extending, extension, focusing, Frederick, headcount, improvement, initially, interference, led, MD, nonrecurring, noted, OETC, optimization, organic, outage, recovery, refractory, renovated, represent, representative, repurchase, reserved, revoked, sequestration, straight, Thravixa, trademark, twelve, unspecified, venture
Filing tables
Filing exhibits
Related press release
EBS similar filings
Filing view
External links
EXHIBIT 12
Ratio of Earnings to Fixed Charges | ||||||||||||||||||||
Year Ended December 31, | ||||||||||||||||||||
(in thousands) | 2015 | 2014 | 2013 | 2012 | 2011 | |||||||||||||||
Pretax income from continuing operations (1) | $ | 89,769 | $ | 53,062 | $ | 44,243 | $ | 37,446 | $ | 38,849 | ||||||||||
Fixed charges | ||||||||||||||||||||
Interest expense | 7,834 | 7,480 | 1,973 | 2,177 | 1,719 | |||||||||||||||
Debt issuance cost | 1,564 | 3,290 | 319 | 67 | 135 | |||||||||||||||
Total fixed charges (2) | 9,398 | 10,770 | 2,292 | 2,244 | 1,854 | |||||||||||||||
Noncontrolling interest in pretax income (3) | - | - | 876 | 5,381 | 6,906 | |||||||||||||||
Capitalized interest (4) | 2,875 | 2,530 | 1,973 | 2,177 | 1,713 | |||||||||||||||
Earnings ((1) + (2) -(3) -(4)) | 96,292 | 61,302 | 43,686 | 32,132 | 32,084 | |||||||||||||||
Fixed charges | 9,398 | 10,770 | 2,292 | 2,244 | 1,854 | |||||||||||||||
Ratio of earnings to fixed charges | 10.2 | 5.7 | 19.1 | 14.3 | 17.3 |